Danielle Casucci Email

VP Clinical Operations . MimiVax

Current Roles

Employees:
4
Revenue:
$620k
About
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates\n\nMimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. \n\nSurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma. \n\nAdditional indications are being evaluated through: \n- Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) \n- Phase 1 in Neuro-Endocrine Tumors (NET)\n- Pilot Study in Pediatric High Grade Glioma, recurrent/relapsed Medulloblastoma and DIPG
MimiVax Address

Buffalo, NY
United States
MimiVax Email